A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres
A phase 1/2 trial of PM8002, Ipilimumab in hepatocellular carcinoma, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) is a phase 1/2 interventional study registered as NCT07291076 by Bristol-Myers Squibb, with 198 participants planned, started 2026-03-16 and due to reach its primary completion in 2029-10-15. Interventions recorded: Pumitamig, Ipilimumab. Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal
Shares PM8002, Ipilimumab, Bristol Myers Squibb.
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares PM8002, Bristol Myers Squibb.
- TrialA Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung
Shares PM8002, Bristol Myers Squibb.
- TrialA Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
- TrialA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P
Shares PM8002, Bristol Myers Squibb.
- TrialA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell
Shares PM8002, Bristol Myers Squibb.
- TrialA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Shares Ipilimumab, Bristol Myers Squibb.
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Shares PM8002, Bristol Myers Squibb.